1–5 of 5
Uhohinc's profile photo
Uhohinc, … Claes Svensson41
7/25/23
AP1189 a Erk1/2 pathway without Mcr1 or Mcr3 activation, I do not see as a commercial threat to afamelanotide. Hruby patent for Mcr3 selectivity has gone nowhere.
The resomelagon (AP1189) Development Program Our Lead Program: Resomelagon (AP1189) SynAct's drug candidate, resomelagon (AP1189), is a once-daily
unread,
AP1189 a Erk1/2 pathway without Mcr1 or Mcr3 activation, I do not see as a commercial threat to afamelanotide. Hruby patent for Mcr3 selectivity has gone nowhere.
The resomelagon (AP1189) Development Program Our Lead Program: Resomelagon (AP1189) SynAct's drug candidate, resomelagon (AP1189), is a once-daily
7/25/23
Uhohinc's profile photo
Uhohinc8
10/10/20
Mallinckrodt bought its potential melanocortin competitors to shut off other drugs and brags the Federal Trade Commission settlement requiring a licensure of synthactin by FTC is
https://www.thestreet.com/investing/mallinckrodt-close-to-bankruptcy-deal-report-says Near bankruptcy.....fda gave letter deny of drug .....not
unread,
Mallinckrodt bought its potential melanocortin competitors to shut off other drugs and brags the Federal Trade Commission settlement requiring a licensure of synthactin by FTC is
https://www.thestreet.com/investing/mallinckrodt-close-to-bankruptcy-deal-report-says Near bankruptcy.....fda gave letter deny of drug .....not
10/10/20
Farma Zutical's profile photo
Farma Zutical, … Uhohinc56
8/11/19
It seems a teenager is trying to buy us out
melanocortin drug Synthactin) the FDA followed procedurals and protocolls and resulted in delays to FDA doing its MAA meeting. My understanding..... A short sale contract has a date
unread,
It seems a teenager is trying to buy us out
melanocortin drug Synthactin) the FDA followed procedurals and protocolls and resulted in delays to FDA doing its MAA meeting. My understanding..... A short sale contract has a date
8/11/19
Uhohinc's profile photo
Uhohinc
2/11/17
Skhreli apparently was impetus for FDA and Justice department to go after Mallinckrodt and find horrendously increase in what is the melanocortins drug Synthactin (an acth) Skhreli has been a catalyst for political focus on drug pricing and FDA redo
'Gaming the system': FDA approves old drug with new price – more than 7000 percent higher! https://www.rt.com/usa/377033-fda-approves-drug-
unread,
Skhreli apparently was impetus for FDA and Justice department to go after Mallinckrodt and find horrendously increase in what is the melanocortins drug Synthactin (an acth) Skhreli has been a catalyst for political focus on drug pricing and FDA redo
'Gaming the system': FDA approves old drug with new price – more than 7000 percent higher! https://www.rt.com/usa/377033-fda-approves-drug-
2/11/17
itunes...@gmail.com's profile photo
itunes...@gmail.com, Uhohinc19
11/29/21
Acthar and Questcor pharmaceuticals is a 2-3Billion dollar company with an inferior product
In this period of extreme quietness. I have been doing some reading. This story may have been raised
unread,
Acthar and Questcor pharmaceuticals is a 2-3Billion dollar company with an inferior product
In this period of extreme quietness. I have been doing some reading. This story may have been raised
11/29/21